Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,883 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenue
56,330
56,330
51,722
46,660
43,375
43,974
Revenue Growth (YoY)
9%
9%
11%
8%
-1%
-12%
Cost of Revenue
13,620
13,620
12,815
12,020
11,211
11,391
Gross Profit
42,710
42,710
38,907
34,640
32,164
32,583
Selling, General & Admin
13,238
13,238
12,564
12,489
12,193
12,756
Research & Development
10,295
10,295
9,302
8,600
9,378
8,150
Operating Expenses
24,018
24,018
22,587
21,998
21,958
21,620
Other Non Operating Income (Expenses)
44
44
-85
-60
-115
-108
Pretax Income
16,352
16,352
13,640
9,123
7,177
24,530
Income Tax Expense
2,385
2,385
1,701
551
1,128
1,625
Net Income
13,984
13,984
11,941
14,850
6,955
24,021
Net Income Growth
17%
17%
-20%
113.99%
-71%
198%
Shares Outstanding (Diluted)
1,929
1,955
2,035
2,092
2,197
2,260
Shares Change (YoY)
-4%
-4%
-3%
-5%
-3%
-2%
EPS (Diluted)
7.24
7.15
5.87
7.09
3.16
10.62
EPS Growth
22%
22%
-17%
124%
-70%
202%
Free Cash Flow
15,244
15,244
13,805
11,705
11,565
12,100
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
75.82%
75.82%
75.22%
74.23%
74.15%
74.09%
Operating Margin
33.18%
33.18%
31.55%
27.09%
23.52%
24.93%
Profit Margin
24.82%
24.82%
23.08%
31.82%
16.03%
54.62%
Free Cash Flow Margin
27.06%
27.06%
26.69%
25.08%
26.66%
27.51%
EBITDA
24,017
24,017
20,919
20,919
17,387
17,076
EBITDA Margin
42.63%
42.63%
40.44%
44.83%
40.08%
38.83%
D&A For EBITDA
5,325
5,325
4,599
8,277
7,181
6,113
EBIT
18,692
18,692
16,320
12,642
10,206
10,963
EBIT Margin
33.18%
33.18%
31.55%
27.09%
23.52%
24.93%
Effective Tax Rate
14.58%
14.58%
12.47%
6.03%
15.71%
6.62%
Follow-Up Questions
What are Novartis AG's key financial statements?
According to the latest financial statement (Form-10K), Novartis AG has a total asset of $110,949, Net profit of $13,984
What are the key financial ratios for NVS?
Novartis AG's Current ratio is 1.71, has a Net margin is 24.82, sales per share of $28.81.
How is Novartis AG's revenue broken down by segment or geography?
Novartis AG largest revenue segment is Other, at a revenue of 2,142,000,000 in the most earnings release.For geography, United States Revenue (Post-Q2 2023 Reporting) is the primary market for Novartis AG, at a revenue of 23,331,000,000.
Is Novartis AG profitable?
yes, according to the latest financial statements, Novartis AG has a net profit of $13,984
Does Novartis AG have any liabilities?
yes, Novartis AG has liability of 64,819
How many outstanding shares for Novartis AG?
Novartis AG has a total outstanding shares of 1,918.79